Pre-Market NASDAQ Movers (WCAA, TIBX, CECO, IPGP, CSIQ, ALSK, NEOG, VVUS, BBBY, TRIP)

The top pre-market NASDAQ gainers Friday are: WCA Waste Corp., Tibco Software, Career Education, IPG Photonics and Canadian Solar. The top pre-market NASDAQ losers are: Alaska Communications, Neogen, Vivus, Bed Bath & Beyond and TripAdvisor.

Gainers:

WCA Waste Corp. (NASDAQ:WCAA) shares surged 30.35 percent, or $1.49, to $6.40 after it agreed to be acquired by Macquarie Infrastructure Partners II for about $526 million or 6.50 a share in cash.

Shares of Tibco Software, Inc. (NASDAQ:TIBX) advanced 5.41 percent, or $1.19, to $23.19 after reporting better-than-expected quarterly results.

Career Education Corp. (NASDAQ:CECO) shares rose 4.73 percent, or 32 cents, to $7.09.

IPG Photonics Corp. (NASDAQ:IPGP) shares edged up 4.40 percent, or $1.49, to $35.39.

Shares of Canadian Solar, Inc. (NASDAQ:CSIQ) advanced 3.81 percent, or 11 cents, to $3.

Losers:

Shares of Alaska Communications Systems Group, Inc. (NASDAQ:ALSK) plunged 23.69 percent, or $1.04, to $3.35 after it cut its dividend. The company's board has approved a fourth quarter dividend of 5 cents per share. On an annualized basis, this represents a dividend level of 20 cents per share compared to prior level of 86 cents per share, allowing the company to retain $29.8 million cash on an annualized basis.

Neogen Corp. (NASDAQ:NEOG) shares plummeted 15.11 percent, or $4.85, to $27.25 after it reported lower-than-expected quarterly earnings. Neogen's profit for the second quarter fell to $5.24 million or 22 cents per share from $6.11 million or 26 cents per share last year. Analysts expected earnings of 27 cents a share, according to Thomson Reuters.

Vivus, Inc. (NASDAQ:VVUS) shares fell 13.85 percent, or $1.44, to $8.96. The company announced that the U.S. Food and Drug Administration (FDA) is scheduled to review the company's New Drug Application (NDA) for Qnexa for the treatment of obesity on Feb. 22, 2012 . The company resubmitted the NDA on Oct. 17, 2011 seeking approval to market Qnexa in the United States. The FDA accepted the NDA for review on Nov. 3, 2011. The target date for the FDA to complete its review of the Qnexa NDA is April 17, 2012.

Bed Bath & Beyond, Inc. (NASDAQ:BBBY) declined 3.87 percent, or $2.38, to $59.05.

TripAdvisor, Inc. (NASDAQ:TRIP) dropped 2.06 percent, or 57 cents, to $27.10.